Google
ASND 株価分析 — ASCENDIS PHARMA AS (Healthcare >> Biotechnology)
ASND に関するよくある質問
ASNDのPER（株価収益率）は？
ASCENDIS PHARMA AS（ASND）は現在PER 25.74倍で取引されています。
ASNDのROE（自己資本利益率）は？
ASCENDIS PHARMA ASのROEは103.71%です。
ASNDの配当利回りは？
ASCENDIS PHARMA ASの配当利回りは0.00%です。
ASNDの品質スコア（Quality Score）は？
当社のAIはASNDの総合財務品質を100点中46点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
ASNDは今が買い時ですか？
当社AIのタイミングスコアは100点中70点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
ASNDはどのセクターに属しますか？
ASCENDIS PHARMA ASはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
ASND AI Analysis Summary
Our AI summary for ASND: ASCENDIS PHARMA AS (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 25.74, ROE of 103.71%, a dividend yield of 0.00%. Its financial Quality Score stands at 46/100 — fundamentals below the market average. The AI Timing Score is 70/100 — multiple technical signals currently support price momentum. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 243.91
Price
-7.16
(-2.85%)
Day Change
|
|
|---|
ASND, ファンダメンタルスコアはnot good ( ファンダメンタル = 46) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEの伸びが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
NPMの伸びが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are not good , financial health is not good , and ability to make profit is ok , ...
| Deepscope 分析 |
|
47% |
| In Recommendations? | In "Invest - GROWTH" Section |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 93 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 243.91 |
| PBV / Sector |
33.71 / 5.20
|
| Earning Per Share | 7.50 |
| PE / Sector |
25.74 / 19.97
|
| PEG or PE/Growth / Sector |
N/A / 1.22
|
| Average 1M Daily Value |
129.55 M
GREAT
|
| Average 1W Daily Value |
120.20 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| ポイントになる統計 |
|
60% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 07:59:30 |
| Symbol | ASND |
| Name | ASCENDIS PHARMA AS |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 65.59 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 16,468.39 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Tuborg Boulevard 12, Hellerup, Denmark, 2900
Phone: 45 70 22 22 44
Website: https://ascendispharma.com
Employees: 1,189
Sector: Healthcare >> Biotechnology
Description: Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
